Hipertansif Hastalarda Atriyal Fibrilasyon Sıklığı

Meral Ekim; Hasan Ekim; Sameh Alagha

doi:10.5281/zenodo.8233496

Yazarlar

Meral Ekim Yozgat Bozok Üniversitesi Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, Yozgat, Türkiye https://orcid.org/0000-0002-7146-5935
Hasan Ekim Yozgat Bozok Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD, Yozgat, Türkiye https://orcid.org/0000-0002-7245-3872
Sameh Alagha Yozgat Bozok Üniversitesi Tıp Fakültesi, Kalp ve Damar Cerrahisi AD, Yozgat, Türkiye https://orcid.org/0000-0002-7892-5471

DOI:

https://doi.org/10.5281/zenodo.8233496

Anahtar Kelimeler:

Hipertansiyon, Atriyal Fibrilasyon, D Vitamini

Özet

Hipertansiyon, atriyal fibrilasyon (AF) ve felce yol açabilen dünya çapında önemli bir sağlık sorunudur. Epidemiyolojik çalışmalar, hipertansiyonun AF'nin en yaygın nedenlerinden birisi olduğunu göstermiştir. AF ister semptomatik isterse asemptomatik olsun inme veya sistemik tromboembolizm riskini önemli ölçüde arttıran bir risk faktörüdür. Çalışmamızın amacı hipertansif hastalarda AF sıklığını araştırmaktır.

Çalışmamızda Aralık 2020 ile Haziran 2023 tarihleri arasında antihipertansif tedavi gören 80 yetişkin hastada AF sıklığı araştırılmıştır. AF, tanısı ve araştırılması için aralıklı standart 12 derivasyonlu elektrokardiyogramlar (EKG) çekildi. Hastaların rutin laboratuvar ve radyolojik tetkiklerin yanında 25-hidroksivitamin D (25(OH)D), B12 vitamini, magnezyum ve folat seviyeleri de ölçüldü. Bulgularımız ortalama ± standart sapma (SS) olarak belirtildi. İstatistiksel analiz için t testi kullanıldı ve 0,05'ten küçük bir p değeri istatistiksel olarak anlamlı olarak değerlendirildi.

Çalışmaya katılan 40 (%50) hasta kadın ve 40 (%50) hasta erkek idi. Hastaların yaşları 45 ile 84 arasında değişmekte ve ortalama yaşta 65.2±7.9 yıldı. Onu erkek ve 10’u kadın olmak üzere toplam 20 (%25) hastada AF tespit edildi. AF olan hastaların yaş ortalaması 66.5±7.7 yıl idi. AF tespit edilen hastalarda ortalama yaş anlamlı olarak yüksekti (p<0.05). Ayrıca, AF olan hipertansiflerde sinüs ritminde olanlara göre ortalama D vitamini düzeyi anlamlı olarak daha azdı (p<0.05).

Hipertansif hastalarda AF oranı yüksektir. Hipertansiyonun kontrol altına alınması, ritim kontrolü, kalp yetmezliği ve AF ile inmenin önlenmesi için esastır. Ayrıca hipertansiyon ve AF birbirlerine eğilim oluşturur. Çalışmamız AF olan hipertansif hastalarda D vitamini eksikliğinin daha sık olduğunu gösterdiğinden hipertansif hastalarda D vitamini düzeyinin de kontrol edilmesini öneririz.

Referanslar

Angeli F, Reboldi G, Trapasso M, et al. European and US guidelines for arterial hypertension: similarities and differences. Eur J Intern Med. 2019;63:3‐8.

Varvarousis D, Kallistratos M, Poulimenos L, Triantafyllis A, Tsinivizov P, Giannakopoulos A, et al Cardiac arrhythmias in arterial hypertension. J Clin Hypertens (Greenwich). 2020;22(8):1371-1378. doi: 10.1111/jch.13989.

Kırali K. Atriyal Fibrilasyonun Tanımlanması.Turkiye Klinikleri J Cardiovasc Surg-Special Topics 2008, 1,4-6.

Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines fort he management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854-906.

Dzeshka MS, Shahid F, Shantsila A, Lip GY. Hypertension and atrial fibrillation: an intimate association of epidemiology, pathophysiology, and outcomes. Am J Hypertens. 2017;30:733–755.

Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease - Double trouble. Adv Med Sci. 2018;63(1):30-35. doi: 10.1016/j.advms.2017.06.005. Epub 2017 Aug 14. PMID: 28818746.

Varvarousis D, Kallistratos M, Poulimenos L, Triantafyllis A, Tsinivizov P, Giannakopoulos A, et al. Cardiac arrhythmias in arterial hypertension. J Clin Hypertens (Greenwich). 2020;22(8):1371-1378. doi: 10.1111/jch.13989.

Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies. Circ Res. 2018;122:352–368.

Hirsh BJ, Copeland‐Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J Am Coll Cardiol. 2015;65:2239‐2251.

Dzeshka MS, Shahid F, Shantsila A, Lip GYH. Hypertension and atrial fibrillation: an intimate association of epidemiology, pathophysiology, and outcomes. Am J Hypertens. 2017;30:733–755.

Barrios V, Escobar C, Prieto Valiente L, Lobos JM, Vargas-Ortega D, Polo J, et al. Blood pressure control in anticoagulated patients with hypertension and atrial fibrillation. Blood Press. 2017 Oct;26(5):279-283. doi: 10.1080/08037051.2017.1313094. Epub 2017 Apr 7. PMID: 28385080.

Rahman F, Yin X, Larson MG, Ellinor PT, Lubitz SA, Vasan RS, et al. Trajectories of risk factors and risk of new-onset atrial fibrillation in the Framingham Heart Study. Hypertension. 2016;68:597–605. doi: 10.1161/HYPERTENSIONAHA.116.07683.

Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial fibrillation and hypertension. Hypertension. 2017;70:854–861.

Mikhail S. Dzeshka, Alena Shantsila, Eduard Shantsila, Gregory Y.H. Lip.Atrial Fibrillation and Hypertension.Hypertension. 2017;70:854-861. DOI: 10.1161/HYPERTENSIONAHA.117.08934.

Demir M, Uyan U, Melek M. The effects of vitamin D deficiency on atrial fibrillation. Clin Appl Thromb Hemost. 2014;20(1):98-103. doi: 10.1177/1076029612453762.

Kallistratos MS, Poulimenos LE, Manolis AJ. Atrial fibrillation and arterial hypertension. Pharmacol Res. 2018;128:322-6.

Bosch NA, Cimini J, Walkey AJ. Atrial Fibrillation in the ICU. Chest. 2018;154(6):1424-1434. doi: 10.1016/j.chest.2018.03.040. Epub 2018 Apr 6. PMID: 29627355; PMCID: PMC6335260.

Kalogeropoulos A, Tsiodras S, Rigopoulos A, et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord. 2011;11:77.

Manolis AJ, Kallistratos MS, Poulimenos LE. Recent clinical trials in atrial fibrillation in hypertensive patients. Curr Hypertens Rep. 2012;14(4):350-9. doi: 10.1007/s11906-012-0268-5. PMID: 22576674.

Mitchell GF. Arterial stiffness and hypertension. Hypertension. 2014;64:13–18. doi: 10.1161/HYPERTENSIONAHA.114.00921.

Mugnai G, Arcaro G, Vassanelli C. Echocardiographically derived pulse wave velocity and diastolic dysfunction are associated with an increased incidence of atrial fibrillation in patients with systolic heart failure. Echocardiography. 2016;33:1024–1031.

Patel N, O’Neal WT, Whalen SP, Soliman EZ. Electrocardiographic left ventricular hypertrophy predicts atrial fibrillation independent of left ventricular mass. Ann Noninvasive Electrocardiol. 2017;22:1–5. doi: 10.1111/anec.12419.

Nagarakanti R, Wallentin L, Noack H, et al. Comparison of characteristics and outcomes of Dabigatran versus Warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial). Am J Cardiol. 2015;116:1204–1209.

Gepner AD, Tedla Y, Colangelo LA, Tattersall MC, Korcarz CE, Kaufman JD, Liu K, Burke GL, Shea S, Greenland P, Stein JH. Progression of carotid arterial stiffness with treatment of hypertension over 10 years: the Multi-Ethnic Study of Atherosclerosis. Hypertension. 2017;69:87–95.

Go O, Rosendorff C. Hypertension and atrial fibrillation. Curr Cardiol Rep. 2009;11(6):430-5. doi: 10.1007/s11886-009-0062-4. PMID: 19863867.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Eur Heart J. 2016;37(38):2893-2962.

Kallistratos MS, Poulimenos LE, Manolis AJ. Atrial fibrillation and arterial hypertension. Pharmacol Res. 2018;128:322-6.

Yiğit E, Erciyes D. Role of Insulin Resistance in the Development of Atrial Fibrillation.Nam Kem Med J 2022;10(3):265-269.DOI: 10.4274/nkmj.galenos.2022.31932.

Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019;21:210-7.

Chan YH, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, et al. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. Cardiovasc Diabetol. 2019;18:125.

Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123.

Korantzopoulos P, Letsas K, Fragakis N, Tse G, Liu T. Oxidative stress and atrial fibrillation: an update. Free Radic Res. 2018;52(11-12):1199-1209. doi: 10.1080/10715762.2018.1500696.

Kim YM, Kattach H, Ratnatunga C, et al. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008;51:68–74.

Sovari AA, Morita N, Karagueuzian HS. Apocynin: a potent NADPH oxidase inhibitor for the management of atrial fibrillation. Redox Rep. 2008;13:242–5.

Costanzo S, De Curtis A, di Niro V, et al. Postoperative atrial fibrillation and total dietary antioxidant capacity in patients undergoing cardiac surgery: The Polyphemus Observational Study. J Thorac Cardiovasc Surg. 2015;149:1175–1182.e1.

Guarracini F, Tritto M, Di Monaco A, Mariani MV, Gasperetti A, Compagnucci P, et al. Stereotactic Arrhythmia Radioablation Treatment of Ventricular Tachycardia: Current Technology and Evolving Indications. J Cardiovasc Dev Dis. 2023 Apr 17;10(4):172.

Emdin CA, Anderson SG, Salimi-Khorshidi G, Woodward M, MacMahon S, Dwyer T, Rahimi K. Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. Int J Epidemiol. 2017;46:162–172.

Rahman F, Yin X, Larson MG, Ellinor PT, Lubitz SA, Vasan RS, et al. Trajectories of risk factors and risk of new-onset atrial fibrillation in the Framingham Heart Study. Hypertension. 2016;68:597–605. doi: 10.1161/HYPERTENSIONAHA.116.07683.

Lip GY. Atrial fibrillation in patients with hypertension: trajectories of risk factors in yet another manifestation of hypertensive target organ damage. Hypertension. 2016;68:544‐545.

Manolis AJ, Kallistratos M, Poulimenos L. Recent clinical trials in atrial fibrillation in hypertensive patients. Curr Hyperts Rep. 2012;14:350‐359.

Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96(4):1180–1184.

Cerit L, Özcem B, Cerit Z, Duygu H. Preventive Effect of Preoperative Vitamin D Supplementation on Postoperative Atrial Fibrillation. Braz J Cardiovasc Surg. 2018;33(4):347-352. doi: 10.21470/1678-9741-2018-0014.

Hipertansif Hastalarda Atriyal Fibrilasyon Sıklığı

Yazarlar

DOI:

Anahtar Kelimeler:

Özet

Referanslar

İndir

Yayınlanmış

Nasıl Atıf Yapılır

Sayı

Bölüm

Lisans

Aynı yazar(lar)ın dergideki en çok okunan makaleleri

Makale Gönder

Dil

Bilgi